Celludoxa Sanovazo – A Class II Medical Device Trauma Dressing from Patented Process Soybean Extract
Celludoxa Sanovazo - A Class II Medical Device Trauma Dressing from Patented Process Soybean Extract
Charsire Biotechnology Corp.
Celludoxa Sanovazo - A Class II Medical Device Trauma Dressing from Patented Process Soybean Extract
Charsire Biotechnology Corp.
Back to Hall of Fame
Cancer is one of the leading causes of death in
the global population. Statistics indicates that
the number of people diagnosed with cancer
globally is large and is increasing. More than
half of cancer patients need to undergo
radiotherapy during their treatment courses.
However, the side effects on skin associated
with radiotherapy cause interruption of the
treatment which leads to the attenuation of
treatment efficacy.
The Celludoxa Sanovazo Trauma Dressing
functions in maintaining the skin around
the wound in a moisturising environment,
promoting skin tissue regeneration for
patients undergoing radiotherapy. (96% of
patients who used Sanovazo developed Grade
1 or less dermatitis). The active ingredient is
derived from the patented plant extracts,
which is natural and safe for wound healing.
The small molecules can be easily absorbed
by skin, which makes wound healing more
efficient.
The Celludoxa Sanovazo Trauma Dressing
is a Class II medical device topical dressing
manufactured by incorporating topical
formulation of Charsire Biotechnology
Corp. and extracts from the patented
manufacturing processes of Charsire
Biotechnology Corp. Celludoxa Sanovazo
is granted patents by countries including
Taiwan, the United States, Canada, Australia,
Japan, etc.
Highlights
- Skin Protection Potential for Radiotherapy Skin Side Effects: The Celludoxa Sanovazo can effectively minimise the side effects of radiotherapy on the skin.
- The Source of Functional Ingredient is from a Single Common Plant: The main ingredient source of Celludoxa Sanovazo trauma dressing is the staple crop “soybean” for daily consumption. The difference in the main raw materials makes the quality control of Sanovazo relatively simple, which further reduces the costs of quality control.
- Solid Toxicological Safety Research: The safety of Celludoze Sanovaz trauma dressing has undergone complete toxicological studies required before entering Phases II and Phase III clinical trials of external dosage forms new drugs, including genetic level, cross-species, oral, topical, central nervous, respiratory, cardiovascular system and other in-depth safety tests.
- Winner of “2021 Pharmaceutical Technology Research and Development Award” organised by the Ministry of Health and Welfare and Ministry of Economic Affairs.
- Winner of “National Innovation Award” organised by the Institute for Biotechnology and Medicine Industry.
View Website
Back to Hall of Fame
Cancer is one of the leading causes of death in
the global population. Statistics indicates that
the number of people diagnosed with cancer
globally is large and is increasing. More than
half of cancer patients need to undergo
radiotherapy during their treatment courses.
However, the side effects on skin associated
with radiotherapy cause interruption of the
treatment which leads to the attenuation of
treatment efficacy.
The Celludoxa Sanovazo Trauma Dressing
functions in maintaining the skin around
the wound in a moisturising environment,
promoting skin tissue regeneration for
patients undergoing radiotherapy. (96% of
patients who used Sanovazo developed Grade
1 or less dermatitis). The active ingredient is
derived from the patented plant extracts,
which is natural and safe for wound healing.
The small molecules can be easily absorbed
by skin, which makes wound healing more
efficient.
The Celludoxa Sanovazo Trauma Dressing
is a Class II medical device topical dressing
manufactured by incorporating topical
formulation of Charsire Biotechnology
Corp. and extracts from the patented
manufacturing processes of Charsire
Biotechnology Corp. Celludoxa Sanovazo
is granted patents by countries including
Taiwan, the United States, Canada, Australia,
Japan, etc.
Highlights
- Skin Protection Potential for Radiotherapy Skin Side Effects: The Celludoxa Sanovazo can effectively minimise the side effects of radiotherapy on the skin.
- The Source of Functional Ingredient is from a Single Common Plant: The main ingredient source of Celludoxa Sanovazo trauma dressing is the staple crop “soybean” for daily consumption. The difference in the main raw materials makes the quality control of Sanovazo relatively simple, which further reduces the costs of quality control.
- Solid Toxicological Safety Research: The safety of Celludoze Sanovaz trauma dressing has undergone complete toxicological studies required before entering Phases II and Phase III clinical trials of external dosage forms new drugs, including genetic level, cross-species, oral, topical, central nervous, respiratory, cardiovascular system and other in-depth safety tests.
- Winner of “2021 Pharmaceutical Technology Research and Development Award” organised by the Ministry of Health and Welfare and Ministry of Economic Affairs.
- Winner of “National Innovation Award” organised by the Institute for Biotechnology and Medicine Industry.
View Website